Literature DB >> 30315576

Balanitis xerotica obliterans: a review of diagnosis and management.

Olivia A Charlton1, Saxon D Smith1,2.   

Abstract

Balanitis xerotica obliterans (BXO), or penile lichen sclerosus, is a progressive sclerosing inflammatory dermatosis of the glans penis and foreskin. It is associated with significant morbidity and may result in impaired urinary and sexual function. It was initially described by Stuhmer in 1928, named after its pathological features, and is considered the male equivalent of vulvar lichen sclerosis (LS).3,40 The etiology of BXO is uncertain; however, autoimmune disease, local trauma, and genetic and infective causes have been proposed. BXO occurs most commonly on the prepuce and glans penis. It is considered to have premalignant potential to transform into squamous neoplasia. This postulation rests on retrospective studies and parallels drawn with vulvar LS and squamous cell carcinoma (SCC) development. Histologically, BXO and vulvar LS are considered the same disease.41 There is a paucity of evidence-based guidelines to assist with appropriate follow-up for patients with BXO.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30315576     DOI: 10.1111/ijd.14236

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

Review 1.  Balanitis xerotica obliterans: an update for clinicians.

Authors:  Alexander T M Nguyen; Andrew J A Holland
Journal:  Eur J Pediatr       Date:  2019-11-23       Impact factor: 3.183

2.  Could a careful clinical examination distinguish physiologic phimosis from balanitis xerotica obliterans in children?

Authors:  Filippo Ghidini; Calogero Virgone; Rebecca Pulvirenti; Emanuele Trovalusci; Piergiorgio Gamba
Journal:  Eur J Pediatr       Date:  2020-11-23       Impact factor: 3.183

3.  Hypopigmented penile fixed drug eruption.

Authors:  Perpetua U Ibekwe; Hafees O Ajibola; Zainabb Babba; Grace Otokpa; Raphael Solomon; Bob A Ukonu
Journal:  Clin Case Rep       Date:  2022-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.